AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16703579
Drug: Aztreonam lysinate
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aztreonam lysinate for inhalation (AI) 225 mg (adolescents)
Trial: 16703579
Drug: Aztreonam lysinate
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aztreonam lysinate for inhalation (AI) 75 mg (adults)
Trial: 16703579
Drug: Aztreonam lysinate
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aztreonam lysinate for inhalation (AI)
Trial: 11878737
Drug: PCEA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA plus night-time infusion
Trial: 823586
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg chlordiazepoxide
Trial: 26408873
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus glimepiride (3mg once daily)
Trial: 26408873
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus gliclazide (80 mg once daily)
Trial: 21645895
Drug: ethinilestradiol (EE)
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinilestradiol (EE) 0.020 mg + DRSP 3 mg
Trial: 21645895
Drug: ethinilestradiol (EE)
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ethinilestradiol (EE) 0.020 mg + desogestrel 0.15 mg
Trial: 15138107
Drug: lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine 100 mg daily
Trial: 9732194
Drug: Saline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (2 ml) administered intramuscularly 45 min before ESWL
Trial: 28274234
Drug: Sapropterin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin (10 mg/kg/day) plus phenylalanine-restricted diet
Trial: 21419010
Drug: Local anesthetics
RxNorm normalized name: LOCAL ANESTHETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetics plus 2 µg/kg buprenorphine (B group)
Trial: 21419010
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection 2 µg/kg buprenorphine before anesthesia (C group)
Trial: 15932835
Drug: Bazedoxifene 20
RxNorm normalized name: bazedoxifene 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 20 mg/d
Trial: 15932835
Drug: Bazedoxifene 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 40 mg/d
Trial: 11408508
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/d
Trial: 12679422
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy (9.6 micro g/kg body weight.d)
Trial: 10487455
Drug: Topical mupirocin
RxNorm normalized name: mupirocin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mupirocin therapy
Trial: 31983237
Drug: Topical proparacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical proparacaine 0.5% (additional drop)
Trial: 31983237
Drug: Topical proparacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical proparacaine 0.5% and povidone iodine
Trial: 19875482
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH), 2 mg/d subcutaneously for 8 weeks
Trial: 11171825
Drug: Phenylephrine gel
RxNorm normalized name: LIDOCAINE 50 mg in 1 g / PHENYLEPHRINE HYDROCHLORIDE 2.5 mg in 1 g TOPICAL GEL [SECONDARY NUMB Lidocaine Phenylephrine Gel]
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine gel 20%
Trial: 30577404
Drug: Initial radiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial radiation therapy
Trial: 11939936
Drug: Entacapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (200 mg)
Trial: 1743245
Drug: Nitrazepam 5
RxNorm normalized name: nitrazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 5 mg/d
Trial: 31467115
Drug: Inhaled α1-antitrypsin
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled α1-antitrypsin (AAT) 80 mg solution, twice daily for 50 weeks
Trial: 24639423
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium nitrite (70 μmol) administered over 5 min immediately before primary percutaneous intervention (PPCI)
Trial: 24639423
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching infusion)
Trial: 20206784
Drug: L‐AmB 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐AmB 5 mg/kg per week
Trial: 10489946
Drug: Continued medication
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medication
Trial: 2414253
Drug: Bleomycin injected
RxNorm normalized name: bleomycin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin injected intramuscularly 1 hour before radiation treatment daily for 5 days a week
Trial: 19237438
Drug: Heparin-bonded catheters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded catheters
Trial: 19237438
Drug: Standard non-heparin-bonded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard non-heparin-bonded catheters
Trial: 28216062
Drug: Nalmefene (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene (18 mg)
Trial: 29729957
Drug: GM-SR 4/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-SR 4/1000 mg once-daily
Trial: 24123094
Drug: Dose C
RxNorm normalized name: Naprelan Dose Card
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose C (10 mg mane and 5 mg tarde)
Trial: 24123094
Drug: Dose B
RxNorm normalized name: Aldose beta-D-fructosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose B (10 mg mane and 10 mg tarde)
Trial: 24123094
Drug: Dose A
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose A (20 mg mane and 10 mg tarde)
Trial: 21364772
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (DA) therapy
Trial: 21364772
Drug: No DA
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No DA therapy (off DA therapy)
Trial: 19343887
Drug: OXY‐TDS (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXY‐TDS (transdermal oxybutynin)
Trial: 10871974
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 or 30 mg once daily
Trial: 29480324
Drug: EGCG-concentrated green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG-concentrated green tea extract (GTE) low dose
Trial: 29480324
Drug: EGCG-concentrated green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG-concentrated green tea extract (GTE) high dose
Trial: 16505520
Drug: Parenteral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral group
Trial: 16454441
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/d)
Trial: 10344062
Drug: Enalapril 2.5
RxNorm normalized name: enalapril 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 2.5 mg
Trial: 10938492
Drug: Perindopril 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2.0 mg
Trial: 8392282
Drug: Enalaprilat 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat 1.5 mg (intravenous)
Trial: 24671453
Drug: Oral rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rabeprazole 20 mg twice daily for 5 days before ESD
Trial: 24671453
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily for 5 days before ESD
Trial: 19062727
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy with paclitaxel (175 mg/m2) and epirubicin (60 mg/m2) every two weeks
Trial: 28196674
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy
Trial: 19062727
Drug: Regular chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular chemotherapy
Trial: 15452681
Drug: Placebo (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control) with low dose methamphetamine (15 mg)
Trial: 15452681
Drug: Placebo (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control) with high dose methamphetamine (30 mg)
Trial: 12593523
Drug: Beclometasone dipropionate
RxNorm normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 1,600 microg day(‐1) b.i.d. (n = 75)
Trial: 12593523
Drug: Beclometasone dipropionate
RxNorm normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate (BDP) spray 800 microg day(‐1) b.i.d. via metered-dose inhaler (MDI) plus spacer (n = 76)
Trial: 10578788
Drug: Routine nipple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine nipple care including an ointment (control group)
Trial: 10578788
Drug: Avoidance of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoidance of nipple creams and other products (intervention group)
Trial: 8554224
Drug: 23‐polyvalent pneumococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23‐polyvalent pneumococcal polysaccharide vaccine
Trial: 1677625
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal tablets
Trial: 2195577
Drug: Clonidine (oral)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (oral)
Trial: 6129951
Drug: Propanolol (oral)
RxNorm normalized name: Propanolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propanolol (oral)
Trial: 26156651
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg per day)
Trial: 21761999
Drug: Carbetocin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (single dose)
Trial: 21761999
Drug: Oxytocin (infusion)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin (infusion)
Trial: 16881500
Drug: Ametop (amethocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ametop (amethocaine gel) applied to a digit for 30 minutes before capillary sampling
Trial: 16765148
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray
Trial: 11349825
Drug: Candesartan cilexetil/HCTZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan cilexetil/HCTZ, 16/12.5 mg once daily
Trial: 11349825
Drug: Candesartan cilexetil/placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan cilexetil/placebo, 16 mg once daily
Trial: 3150273
Drug: Conventional immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppressive therapy
Trial: 19258430
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rhGH treatment)
Trial: 2135068
Drug: Actovegin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin (250 ml 20%)
Trial: 19803573
Drug: Cultural congruence
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultural congruence in treatment
Trial: 16940452
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at a mean maintenance dose of 0.31 mg/d in elderly GHD patients
Trial: 16940452
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at a mean maintenance dose of 0.44 mg/d in younger GHD patients
Trial: 14525770
Drug: Itraconazole (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (oral solution 2.5 mg/kg 3 times daily, or intravenous 200 mg daily)
Trial: 10577295
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg/d)
Trial: 2960861
Drug: Etretin (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretin (0, 25, or 50 mg/day for 8 weeks, followed by 25, 50, or 75 mg/day for optimal response)
Trial: 30206079
Drug: Advice, exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice, exercises and soft-tissue treatment plus manipulative therapy
Trial: 30206079
Drug: Advice, exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice, exercises and soft-tissue treatment
Trial: 27257748
Drug: Formulation letters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation letters that paid attention to the development of AN
Trial: 24292991
Drug: Clarithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (1 g intravenously once daily for 4 days)
Trial: 20394631
Drug: C/BPO +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/BPO + PDL treatment (wavelength 585 nm, energy fluence 3 J cm(‐2), pulse duration 0.35 ms, spot size 7 mm)
Trial: 12100223
Drug: rizatriptan 10
RxNorm normalized name: rizatriptan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rizatriptan 10 mg oral
Trial: 318951
Drug: Pentazocine 25
RxNorm normalized name: pentazocine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 25 mg and Aspirin 325 mg (PA-L)
Trial: 318951
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg of Aspirin (A650)
Trial: 318951
Drug: Pentazocine 50
RxNorm normalized name: pentazocine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 50 mg and Aspirin 650 mg (PA-H)
Trial: 30979460
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus with standard-dose corticosteroids
Trial: 30979460
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus with reduced-dose corticosteroids
Trial: 31056218
Drug: Drug (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug (exact dosage and duration not specified)
Trial: 23506415
Drug: Optimal current
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal current step-up practice (medical treatment followed by endoscopic interventions and surgery if needed)
Trial: 19508745
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy for MRKH (CBT-MRKH)
Trial: 15477790
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day) for 6 weeks
Trial: 12204014
Drug: Doxazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (2 to 8 mg/d)
Trial: 15983290
Drug: Chlorthalidone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5 to 25 mg/d)
Trial: 26489704
Drug: DMARD+adalimumab group
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DMARD+adalimumab group (adalimumab 40 mg/every other week)
Trial: 19841966
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (10 mg/kg initially, then two 5 mg/kg doses 24 h apart)
Trial: 16185378
Drug: Risperidone (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (average final dose 1.6 mg/day)
Trial: 8596125
Drug: 300 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ng/ml exogenous Plasmodium falciparum antigens
Trial: 8596125
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with P. falciparum malaria after 4 weeks of chemotherapy
Trial: 26824942
Drug: Ganciclovir-Valganciclovir dosing
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir-Valganciclovir dosing adjusted based on Bayesian prediction model (group B)
Trial: 15991263
Drug: Guidelines plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidelines plus ATP (Atepadene, 90 mg daily for 30 days)
Trial: 8938674
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (lisinopril or enalapril)
Trial: 27832799
Drug: VMAT (Volumetric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMAT (Volumetric Modulated Arc Therapy)
Trial: 25632744
Drug: Zhibai Dihuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhibai Dihuang Pill (ZBDHP), 6 g each time, twice daily for 90 days
Trial: 22189364
Drug: Pneumatic pulsation
RxNorm normalized name: ABG Pulsator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumatic pulsation therapy (5 treatments over 2 weeks)
Trial: 20003782
Drug: Low‐molecular‐weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐molecular‐weight heparin (LMWH)
Trial: 15045190
Drug: Bazoton uno
RxNorm normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazoton uno (459 mg dry extract of stinging nettle roots)
Trial: 11446046
Drug: Low-dose spiral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spiral CT scanning
Trial: 9543646
Drug: Nicotine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (two 22 mg transdermal patches)
Trial: 7515168
Drug: Interferons (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferons (in combination with chemotherapy and other immunological agents)
Trial: 1984505
Drug: Glucose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose administration
Trial: 23514638
Drug: LIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIA with ketorolac 30 mg
Trial: 12201354
Drug: Delapril 30
RxNorm normalized name: Delapril
DrugBank: Delapril (DB13312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril 30 mg plus Indapamide 2.5 mg
Trial: 7030636
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg slow-release metoprolol once daily for 6 weeks
Trial: 7030636
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg conventional metoprolol once daily for 6 weeks
Trial: 21838506
Drug: Levodopa therapy
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa therapy postoperatively
Trial: 11996472
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m2 every 3 weeks)
Trial: 9882028
Drug: Balsalazide 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 3 g daily
Trial: 23728065
Drug: Varenicline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (2 mg/d, titrated during the first week)
Trial: 22215943
Drug: Peg‐α‐2b interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐α‐2b interferon (1.5 μg/kg per week) plus ribavirin (1000‐1200 mg/d) without vitamin D
Trial: 11177331
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin
Trial: 9477005
Drug: Flumazenil (benzodiazepine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (benzodiazepine antagonist)
Trial: 25529979
Drug: LX4211 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX4211 (400 mg for 7 days)
Trial: 18401199
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections with indwelling catheter (Group A)
Trial: 18401199
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections without indwelling catheter (Group B)
Trial: 11495387
Drug: Nursing-led ward
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing-led ward care (treatment group)
Trial: 7820976
Drug: Leucine infusion
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine infusion (1 g h‐1)
Trial: 7820976
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (20 g h‐1)
Trial: 7820976
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of leucine and glucose infusions
Trial: 30536154
Drug: ICH glasdegib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICH glasdegib (100 mg) after high-fat, high-calorie meal
Trial: 30536154
Drug: ICH glasdegib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICH glasdegib (100 mg) with PPI (rabeprazole)
Trial: 25295770
Drug: Activity prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity prescription intervention targeting sedentary intensity